SUPPLEMENTAL REBATE BID SUBMISSION PROCESS

General Information

Supplemental rebate offers are accepted:

1. when a class of drugs is initially reviewed by the Preferred Drug List (PDL) Committee for class equivalency
2. when a new drug becomes available for an already established PDL class, or
3. annually during the supplemental rebate review period for an existing PDL class.

New PDL Class or New Drug

New drugs or new PDL classes are reviewed by the PDL Committee. If deemed equivalent and approved for the PDL, supplemental rebate offers for these products must be submitted to the Kansas Department of Health and Environment (KDHE) -Division of Health Care Finance (DHCF) by the close of business on the fifteenth working day after the PDL Committee meeting date. KDHE-DHCF will not accept offers after the fifteenth working day deadline.

Existing PDL Class

Supplemental rebates are reviewed every year for existing PDL drug classes. This is a KDHE-DHCF administrative procedure and the PDL class is not reviewed by the PDL Committee at this time*. See the schedule below. Interested vendors should submit new or amended agreements by the 1st day of the review period (first column).

**Class reviews at the PDL Committee meetings occur only when there is a new agent in the class or when there is new, compelling, peer reviewed data about the class.*

Supplemental Bid Schedule

Review Period Begins	Contract Period	Drug Class		
January	April - March	Central Nervous System	Non-scheduled Novel Sleep Agents	H8B
		Respiratory	Inhaled Beta 2 Agonists – Long-Acting	J5D
		Respiratory	Inhaled Beta 2 Agonists – Short-Acting	J5D
		Diabetic Agents	DPP-4 Inhibitors	C4J
February	May – April	Cardiovascular Agents	Beta-Blockers	J7C, J7A
		Central Nervous System	Non-benzodiazepine sedative hypnotics	H2E
		Antihyperlipidemics	HMG-CoA Reductase Inhibitors (Statins)	M4D, M4J

SUPPLEMENTAL REBATE BID SUBMISSION PROCESS

Review Period Begins	Contract Period	Drug Class		
March	June – May	Cardiovascular Agents	Calcium Channel Blockers (Dihydropyridines)	A9A
		Cardiovascular Agents	Calcium Channel Blockers (Non-Dihydropyridines)	A9A
		Injectables	Erythropoiesis - Stimulating Agents	N1B
April	July – June	Osteoporosis Agents	Bisphosophonates	P4L
		Respiratory	Inhaled Corticosteroids	P5A
		Urological Agents	Anticholinergics	R1A, R1I
May	August - July	Injectables	Growth Hormones	P1A
		Analgesics	Drugs for Migraines - Triptans	H3F
		Biologics	Adult Rheumatoid Arthritis Ankylosing Spondylitis Crohn's Disease Plaque Psoriasis Psoriatic Arthritis Ulcerative Colitis	D6A, L1A, S2J, S2M, S2Q, Z2R, Z2U, Z2W
		Cardiovascular Agents	Angiotensin Receptor Antagonist & Calcium Channel Blocker Combos	A4H
		Diabetic Agents	Insulin – Delivery Systems Long Acting Insulin – Vials Only	C4G C4J
June	September - August	Diabetic Agents	Biguanides	C4L
		Analgesics	Muscle Relaxants (Skeletal and Spasticity)	H6H
		Allergy Agents	Ophthalmic Antihistamines/Mast Cell Stabilizers	Q6R
		Allergy Agents	Intranasal Antihistamines	Q7E
July	October - September	Diabetic Agents	Thiazolidinediones	C4N, C4R
		Cardiovascular Agents	ARBs	A4F, A4I
		Cardiovascular Agents	ACE Inhibitors/Calcium Channel Blocker Combos	A4K
		Analgesics	Long-Acting Opioids	H3A

SUPPLEMENTAL REBATE BID SUBMISSION PROCESS

Review Period Begins	Contract Period	Drug Class		Drug Class
August	November - October	Gastrointestinal Agents	H2 Antagonists	Z2D
		Analgesics	Non-Steroidal Anti-Inflammatory (NSAIDs) – Ophthalmic, Oral and Topical	S2B, S2T, Q5E
		Gastrointestinal Agents	Serotonin 5HT3 Antagonists	H6J
		Gastrointestinal Agents	Pancreatic Enzyme Replacement	D8A
September	December - November	Anti-Infectives	Antiherpes Virus Agents	W5A
		Allergy Agents	Non-Sedating Antihistamines	Z2Q
		Nasal Agents	Intranasal Corticosteroids	Q7P
October	January - December	Central Nervous System	Adjunct Antiepileptics	H4B
		Ophthalmic Agents	Ophthalmic Prostaglandin Analogs	Q6G
		Antihyperlipidemics	Fibric Acid Derivatives	M4E
November	February - January	Diabetic Agents	Meglitinides	C4K
		Diabetic Agents	2nd Generation Sulfonylureas	C4S
		Diabetic Agents	Alphaglucosidase Inhibitors	C4M
December	March - February	Cardiovascular Agents	ACE Inhibitors	A4D
		Gout Agents	Xanthine Oxidase Inhibitors	C7A
		Gastrointestinal Agents	Proton Pump Inhibitors	D4J

Step 1: Manufacturer obtains the CMS-approved Supplemental Drug Rebate Agreement and Schedule A (supplemental rebate bid form) at:

http://www.kdheks.gov/hcf/pharmacy/pharmacy_supplemental_rebates.html

Step 2: Manufacturer completes and submits the Supplemental Drug Rebate Agreement and Schedule A.

The manufacturer should complete the contract template/bid form and forward to KDHE-DHCF for review. Bids can be mailed to the following address or submitted electronically to sliby@kdheks.gov. In the subject line of the e-mail, please write "Supplemental Rebate Bid – *Manufacturer Name/Drug Name*".

KDHE-DHCF
Shelly Liby
Landon State Office Building
900 SW Jackson Ave, Suite 900
Topeka, KS 66612

December 8, 2011

SUPPLEMENTAL REBATE BID SUBMISSION PROCESS

All accepted contracts will guarantee that prior authorization will not be required for one year. If a non-preferred drug(s) becomes less costly than the preferred drug(s), that drug(s) may be moved to the preferred list.

Bid Information Required:

1. 11-digit NDC number
2. Product name, strength and dosage form
3. Pricing reference (WAC)
4. Ingredient reimbursement per unit as outlined on Schedule A
5. CMS rebate per unit as outlined on Schedule A
6. Supplemental offer - Fixed net cost to state per unit

Contact Information Required:

1. Manufacturer name
2. Labeler code(s)
3. Contact name and title
4. Mailing address for contact
5. Telephone, fax, cell phone and voice mail numbers
6. E-mail address

Step 3: KDHE-DHCF will notify manufacturer of acceptance or rejection after the net costs have been calculated.